Our Pipeline

 Pioneering Treatment Options for Food Allergies and Beyond

Using our innovative technology platform, we are committed to developing a pipeline of food allergy product candidates that could potentially transform the care of food-allergic patients.

dbvt_devpipeline_chart_v13

Food Allergy Clinical Trials

DBV has designed a robust clinical development program that includes ongoing clinical trials of Viaskin Peanut and Viaskin Milk as well as pre-clinical development of Viaskin Egg.

Viaskin® Peanut Clinical Trials

Peanut allergy is one of the most common food allergies and can cause severe, potentially fatal, allergic reactions, including anaphylaxis.

We have a comprehensive clinical research program in place for Viaskin Peanut. Two Phase III long-term studies in children ages four to 11 are ongoing, as well as a Phase III trial in patients one to three years of age. DBV’s Viaskin Peanut has obtained Fast Track and Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of peanut allergy in children.

* Viaskin® Peanut is an investigational product and has not been approved for any use in any country, including, but not limited to, the United States, Canada, the European Union or Australia.

Viaskin® Milk Clinical Trials

Cow’s Milk Protein Allergy (CMPA) is often the first allergy that appears during early childhood and affects approximately 2 – 3 percent of the population in developed countries.

We have recently completed a Phase I/II trial to study the safety and efficacy of Viaskin Milk in pediatric and adolescent patients. Viaskin Milk was granted U.S. Food and Drug Administration (FDA) Fast Track Designation in September 2016.

*Viaskin® Milk is an investigational product and has not been approved for any use in any country, including, but not limited to, the United States, Canada, the European Union or Australia.

Viaskin® Egg Pre-Clinical Studies

Hen’s egg allergy is one of the most common food allergies in children. Several global studies suggest that egg allergy affects 1.5 – 3 percent of young children.

In the first half of 2015, DBV began pre-clinical work for Viaskin Egg, with the goal of initiating a clinical program if these studies are successful. Preclinical development is currently ongoing.

*Viaskin® Egg is a product under pre-clinical development and has not been approved for any use in any country, including, but not limited to, the United States, Canada, the European Union or Australia.

Other Early Stage Development Programs

Promising Therapeutic Approach Beyond Food Allergies

Viaskin’s potential to unlock the immune properties of the skin makes it a promising therapeutic approach beyond food allergies. DBV is investigating other areas of significant unmet medical need, including Eosinophilic Esophagitis (EoE), vaccines, inflammatory conditions and autoimmune diseases.

Diagnostics

As we focus on diversifying our pipeline, we are also exploring the use of our technology platform in the development of diagnostic tools for food allergies. In 2016, DBV entered an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use and standardized atopy patch test tool for the diagnosis of CMPA in infants and toddlers.